Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 6/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821994 | 0.75 | L3MBTL1 (0.38) | L3MBTL1GAATAS1R3TAS1R1RAB9A | |
| SCHEMBL2819074 | 0.74 | GAA (0.37) | L3MBTL1GAATAS1R3TAS1R1RAB9A | |
| SCHEMBL10315086 | 0.72 | GAA (0.50) | L3MBTL1GAATAS1R3TAS1R1RAB9A | |
| SCHEMBL19464708 | 0.70 | GAA (0.49) | L3MBTL1GAATAS1R3TAS1R1RAB9A | |
| SCHEMBL17221544 | 0.70 | GAA (0.51) | L3MBTL1GAATAS1R3TAS1R1RAB9A | |
| SCHEMBL14345867 | 0.70 | GAA (0.51) | L3MBTL1GAATAS1R3TAS1R1RAB9A | |
| Iodide SCHEMBL2822014 | 0.69 | GAA (0.36) | L3MBTL1GAARAB9A | |
| SCHEMBL8180377 | 0.68 | RAB9A (0.56) | L3MBTL1GAATAS1R3TAS1R1RAB9A | |
| SCHEMBL12600167 | 0.68 | GAA (0.36) | L3MBTL1GAATAS1R3TAS1R1RAB9A | |
| SCHEMBL8201185 | 0.68 | L3MBTL1 (0.49) | L3MBTL1GAATAS1R3TAS1R1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168179-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | KLAR ULRICH | 2010-07-01 | — | — | US | disclosed |
| US-7700621-B2 | E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7645891-B2 | E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-12 | — | — | US | disclosed |
| EP-1173441-B1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | BAYER SCHERING PHARMA AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-7125893-B1 | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | SCHERING AG (DE) | 2006-10-24 | — | — | US | disclosed |
| US-20060046997-A1 | 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-03-02 | — | — | US | disclosed |
| US-20050113429-A1 | 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-05-26 | — | — | US | disclosed |
| EP-1173441-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066589-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046997-A1 | 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | TUBB6, CCNB1, TUBB | L3MBTL1 304/4885GAA 2491/4885TAS1R3 3550/4885 |
| US-20100168179-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | TUBB6, CCNB1, TUBB | L3MBTL1 304/4885GAA 2491/4885TAS1R3 3550/4885 |
| US-20050113429-A1 | 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | TUBB6, CCNB1, TUBB | L3MBTL1 307/4885GAA 2495/4885TAS1R3 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.